Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis

NCT00116649 is registered in ClinicalTrials.gov with Graceway Pharmaceuticals, LLC as lead sponsor.

NCT NCT00116649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00116649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis
Lead sponsor
Graceway Pharmaceuticals, LLC
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2005
Completion date
May 31, 2007
Enrollment
551 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

keratosis